Clinical Trials Logo

Influenza clinical trials

View clinical trials related to Influenza.

Filter by:

NCT ID: NCT04471038 Active, not recruiting - Influenza Clinical Trials

Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants

Start date: July 29, 2020
Phase: Phase 1
Study type: Interventional

Influenza causes substantial morbidity and mortality worldwide despite available antivirals and vaccines. SAB Biotherapeutics, Inc. has developed SAB-176, an anti-influenza human immunoglobulin (transchromosomic [Tc] bovine-derived) intravenous therapeutic to treat past and current strains of Type A Influenza and Type B Influenza. This study will evaluate the safety, tolerability, and pharmacokinetics of SAB-176 in healthy participants.

NCT ID: NCT04460781 Completed - Influenza Clinical Trials

Surveillance Study to Assess the Safety of Flublok Quadrivalent (Influenza Vaccine) in Pregnant Women and Their Offspring

VAP00007
Start date: September 17, 2018
Phase:
Study type: Observational [Patient Registry]

Primary Objective: To evaluate the safety of Flublok Quadrivalent influenza vaccine in pregnant women included in the VAP00003 Study (NCT03694392) and their offspring exposed during pregnancy or up to 28 days preceding the estimated date of conception with regards to pregnancy, birth, and neonatal/infant outcomes Secondary Objective:

NCT ID: NCT04439695 Completed - Influenza Clinical Trials

Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults

Start date: June 25, 2020
Phase: Phase 1
Study type: Interventional

This is an observer-blinded, randomized, placebo-controlled, parallel group study to evaluate safety and immunogenicity of TAP-V001 quadrivalent influenza vaccine in healthy adult subjects.

NCT ID: NCT04385420 Completed - Influenza Clinical Trials

Phase 1 Study of ATR-002

Start date: April 24, 2019
Phase: Phase 1
Study type: Interventional

This was a combination of a single ascending dose (SAD) study to evaluate the safety, tolerability, and PK of 3 oral doses of a MEK inhibitor and a multiple ascending dose (MAD) study of 3 oral doses of a MEK inhibitor. Subjects were to be enrolled in 3 different cohorts in the SAD and 3 different cohorts in the MAD and were to be randomly (blinded) allocated to active treatment or placebo (each cohort consisted of 8 subjects receiving active treatment and 2 subjects receiving placebo).

NCT ID: NCT04377165 Terminated - Influenza Clinical Trials

Innovative Tool to Limit Spread of COVID 19 in Residential Aged Care Facilities

Start date: May 6, 2020
Phase: N/A
Study type: Interventional

This project is a randomised trial in order to determine if "gamification" can result in behaviour change for healthcare workers in the residential aged care setting. The app is for Age Care and care workers at the front line who are working to protect those most vulnerable to COVID-19. There are 2 groups in this trial on group will receive current and accurate information from an app. The other group will receives the app with the addition of a gamification competent, this will include rewarding experiences for staff doing safety behaviours and wellbeing behaviours. The purpose of the gamification is to create a calming and reassuring experience that injects positivity and joy where possible during this stressful time.

NCT ID: NCT04365608 Completed - Influenza Clinical Trials

Prehospital Intubation of COVID-19 Patient With Personal Protective Equipment

Start date: March 20, 2020
Phase: N/A
Study type: Interventional

The safety and efficacy of a laryngoscopy as a primary intubation tool in urgent endotracheal intubation of cardiac arrest patients with suspected/confirmed COVID-19 has not been well-described in the literature. This study will answer whether using a Vie Scope laryngoscope will impact on the efficacy and safety of intubation compared with a traditional direct laryngoscopy.

NCT ID: NCT04363359 Completed - Influenza Clinical Trials

Clinical Trial of Quadrivalent Influenza Virus Split Vaccine

Start date: January 15, 2020
Phase: Phase 2
Study type: Interventional

To evaluate the immunogenicity and safety of 2 doses of quadrivalent influenza virus split vaccine in healthy population aged 6-35 month., so as to provide a data support for phase III clinical trials.

NCT ID: NCT04336020 Recruiting - Influenza Clinical Trials

The DETECT(Digital Engagement & Tracking for Early Control, & Treatment) Study

DETECT
Start date: March 24, 2020
Phase:
Study type: Observational

Develop an app-based nationwide study of individuals who routinely use a smartwatch or other wearable activity tracker to determine if individualized tracking of changes in heart rate, activity and sleep can provide an early indication of influenza-like illnesses (ILI) and possibly other viral infections.

NCT ID: NCT04327791 Recruiting - Influenza Clinical Trials

COmbination Therapy With Baloxavir and Oseltamivir 1 for Hospitalized Patients With Influenza (The COMBO Trial 1)

COMBO 1
Start date: April 3, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

This is a randomized, double-blind, placebo-controlled Phase 2-like, investigator-directed trial of hospitalized patients with laboratory confirmed influenza. Eligible and consented patients will be randomly assigned, in a 1:1 ratio, to one of two groups: Group 1, the combination treatment group (oseltamivir and baloxavir); Group 2, the standard treatment group (oseltamivir and placebo).

NCT ID: NCT04326309 Completed - Healthy Clinical Trials

Audio Data Collection for Identification and Classification of Coughing

Start date: March 25, 2020
Phase:
Study type: Observational

An open access study that will define and collect digital measures of coughing in multiple populations and public spaces using various means of audio data collection.